X Pivot1, I Bondarenko2, Z Nowecki3, M Dvorkin4, E Trishkina5, J-H Ahn6, S-A Im7, T Sarosiek8, S Chatterjee9, M Z Wojtukiewicz10, Y Shparyk11, V Moiseyenko12, M Bello13, V Semiglazov14, Y Lee15, J Lim15. 1. Administrateur de l'Institut Régional du Cancer, 3 rue de la porte de l'hôpital, BP 30042, 67065, Strasbourg Cedex, France. Electronic address: xpivot@strasbourg.unicancer.fr. 2. Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine. 3. Department of Oncology, M Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 4. Department of Oncology, Clinical Oncology Dispensary, Omsk, Russia. 5. Department of Oncology, Leningrad Regional Oncology Centre, St. Petersburg, Russia. 6. Department of Oncology, Asan Medical Center, Seoul, Republic of Korea. 7. Department of Oncology, Seoul National University Hospital, Seoul, Republic of Korea. 8. Department of Clinical Oncology, Centrum Medyczne Ostrobramska NZOZ MAGODENT, Warsaw, Poland. 9. Department of Oncology, Tata Medical Centre, Kolkata, India. 10. Department of Oncology, Medical University of Bialystok, Bialystok, Poland. 11. Chemotherapy Department, Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine. 12. Department of Oncology, N.N. Petrov Cancer Center, St. Petersburg, Russia. 13. Department of Oncology, Saint Luke's Medical Center, Quezon City, Philippines. 14. Department of Oncology, N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia. 15. Biometrics Group (Y. Lee) and Clinical Development Group (J. Lim), Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
Abstract
BACKGROUND: The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanced human epidermal growth factor receptor 2-positivebreast cancer was demonstrated in the previous report. Here, we report the final safety, immunogenicity and survival results after neoadjuvant-adjuvant treatment. PATIENTS AND METHODS: Patients were randomised 1:1 to receive neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide). Patients then underwent surgery, followed by 10 cycles of adjuvant SB3 or TRZ as randomised. End-points included safety, immunogenicity, event-free survival (EFS) and overall survival through the adjuvant period. RESULTS: Of 875 patients randomised, 764 (SB3, n = 380; TRZ, n = 384) completed the study. The median follow-up duration was 437 days in the SB3 group and 438 days in the TRZ group. The incidence of treatment-emergent adverse events was comparable between groups (SB3, 97.5%; TRZ, 96.1%) during the overall study period. Up to the end of study, the overall incidence of antidrug antibody was low in both treatment groups (3 patients each). EFS was comparable between groups with a hazard ratio (SB3/TRZ) of 0.94 (95% confidence interval, 0.59-1.51) and EFS rates at 12 months of 93.7% for SB3 and 93.4% for TRZ. CONCLUSIONS:Final safety, immunogenicity and survival results of this study further support the biosimilarity established between SB3 and TRZ. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02149524); EudraCT (2013-004172-35).
RCT Entities:
BACKGROUND: The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanced humanepidermal growth factor receptor 2-positive breast cancer was demonstrated in the previous report. Here, we report the final safety, immunogenicity and survival results after neoadjuvant-adjuvant treatment. PATIENTS AND METHODS: Patients were randomised 1:1 to receive neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide). Patients then underwent surgery, followed by 10 cycles of adjuvant SB3 or TRZ as randomised. End-points included safety, immunogenicity, event-free survival (EFS) and overall survival through the adjuvant period. RESULTS: Of 875 patients randomised, 764 (SB3, n = 380; TRZ, n = 384) completed the study. The median follow-up duration was 437 days in the SB3 group and 438 days in the TRZ group. The incidence of treatment-emergent adverse events was comparable between groups (SB3, 97.5%; TRZ, 96.1%) during the overall study period. Up to the end of study, the overall incidence of antidrug antibody was low in both treatment groups (3 patients each). EFS was comparable between groups with a hazard ratio (SB3/TRZ) of 0.94 (95% confidence interval, 0.59-1.51) and EFS rates at 12 months of 93.7% for SB3 and 93.4% for TRZ. CONCLUSIONS: Final safety, immunogenicity and survival results of this study further support the biosimilarity established between SB3 and TRZ. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02149524); EudraCT (2013-004172-35).
Authors: Victoria M Youngblood; Ruth Nyirenda; Richard Nyasosela; Takondwa Zuze; Yi Yang; Evaristar Kudowa; Agnes Moses; Jennifer Kincaid; Chifundo Kajombo; Coxcilly Kampani; Fred Chimzimu; Maurice Mulenga; Chrissie Chilima; Grace K Ellis; Ryan Seguin; Maganizo Chagomerana; Rebecca Maine; Sheryl Jordan; Anthony Charles; Clara Lee; Satish Gopal; Tamiwe Tomoka Journal: Cancer Causes Control Date: 2020-03-02 Impact factor: 2.506
Authors: Christoph Suppan; Daniel Steiner; Eva Valentina Klocker; Florian Posch; Elisabeth Henzinger; Hannah Deborah Müller; Herbert Stöger; Nadia Dandachi; Marija Balic Journal: Breast Care (Basel) Date: 2021-02-10 Impact factor: 2.860
Authors: Michael P Lux; Wolfgang Janni; Andreas D Hartkopf; Naiba Nabieva; Florin-Andrei Taran; Friedrich Overkamp; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Johannes Ettl; Jens B Huober; Diana Lüftner; Markus Wallwiener; Volkmar Müller; Matthias W Beckmann; Erik Belleville; Tanja N Fehm; Diethelm Wallwiener; Sara Y Brucker; Andreas Schneeweiss; Peter A Fasching Journal: Geburtshilfe Frauenheilkd Date: 2017-12-18 Impact factor: 2.915
Authors: Mark D Pegram; Igor Bondarenko; Marina Moreira Costa Zorzetto; Sachin Hingmire; Hirotaka Iwase; Petr V Krivorotko; Keun Seok Lee; Rubi K Li; Joanna Pikiel; Rajesh Aggarwal; Reginald Ewesuedo; Amy Freyman; Ray Li; Alicia Vana; Donghua Yin; Charles Zacharchuk; Elizabeth Tan-Chiu Journal: Br J Cancer Date: 2018-12-20 Impact factor: 7.640
Authors: Liese Barbier; Paul Declerck; Steven Simoens; Patrick Neven; Arnold G Vulto; Isabelle Huys Journal: Br J Cancer Date: 2019-07-01 Impact factor: 7.640